underli
health
condit
increas
suscept
sever
includ
hypertens
chronic
obstruct
pulmonari
diseas
diabet
mellitu
cardiovascular
immunocompromis
state
autoimmun
diseas
nonautoimmun
inflammatori
diseas
patient
take
immunosuppress
agent
transplant
organ
activ
cancer
also
increas
suscept
sever
pandem
evolv
incid
rate
cancer
patient
suggest
higher
rate
sever
critic
diseas
one
prospect
cohort
studi
cancer
patient
observ
patient
cancer
higher
risk
sever
event
compar
patient
without
patient
recent
underw
chemotherapi
surgeri
higher
risk
clinic
sever
event
compar
patient
howev
sever
limit
includ
small
sampl
size
differ
cancer
type
variabl
diseas
cours
divers
treatment
strategi
contribut
age
chines
center
diseas
control
prevent
cdc
publish
largest
case
seri
date
mainland
china
report
cfr
among
patient
insuffici
data
current
cancer
patient
requir
examin
past
studi
coronaviru
diseas
immunocompromis
popul
extrapol
risk
suscept
andor
develop
sever
nevertheless
nationwid
analysi
china
observ
patient
cancer
higher
risk
sever
event
compar
patient
without
cancer
patient
underw
chemotherapi
surgeri
previou
month
higher
risk
sever
note
cancer
patient
higher
risk
patient
poorer
outcom
patient
without
immunocompromis
patient
remain
vulner
respiratori
viral
infect
viral
pneumonia
associ
mortal
rate
immunocompromis
specif
convent
coronavirus
shown
associ
higher
rate
oxygen
requir
mortal
patient
hematolog
malign
hematopoiet
cell
one
studi
coronaviru
pneumonia
mortal
cancer
patient
compar
noncanc
furthermor
patient
tend
frequent
prolong
viral
immun
system
alter
sever
way
cancer
patient
put
increas
risk
infect
result
specif
cancer
therapi
extent
diseas
locat
primari
diseas
origin
lymphopenia
observ
patient
advanc
cancer
diseas
patient
local
lymphopenia
seen
varieti
cancer
type
pancreat
melanoma
sarcoma
hepatocellular
nonhodgkin
lymphoma
colon
sever
studi
patient
withhematolog
malignancieswith
respiratori
viral
infect
lymphopenia
independ
predict
progress
laboratori
find
patient
includ
lymphopenia
hospit
patient
nonsurvivor
develop
sever
lymphopenia
platelet
also
play
import
immun
system
role
viricid
effect
cancer
invad
displac
normal
bone
marrow
leukemia
lymphoma
lead
thrombocytopenia
associ
immunocompromis
state
effect
immun
respons
viral
infect
depend
activ
cell
help
clear
infect
recent
studi
patient
nonintens
care
unit
icu
case
decreas
total
cell
wherea
icu
patient
decreas
total
use
corticosteroid
immunosuppress
therapi
risk
factor
sever
respiratori
viral
chemotherapi
damag
bone
marrow
cell
lead
thrombocytopenia
neutropenia
render
patient
suscept
infect
patient
greater
risk
nadir
period
neutrophil
number
lowest
nadir
occur
day
complet
dose
chemotherapi
sometim
last
chemotherapeut
agent
depress
immun
system
cytotox
agent
caus
bone
marrow
suppress
temozolomid
cyclophosphamid
paclitaxel
methotrex
alemtuzumab
increas
infect
risk
cancer
patient
chemotherapi
drug
cyclophosphamid
cisplatin
methotrex
fludarabin
tax
among
potent
agent
result
sinc
limit
data
avail
estim
mortal
risk
patient
undergo
chemotherapi
becom
infect
articleus
model
extrapol
risk
found
cancer
patient
mortal
risk
infect
older
patient
solid
tumor
greater
risk
harm
like
outweigh
benefit
chemotherapi
recommend
made
postpon
adjuv
chemotherapi
stabl
cancer
activ
pandem
area
base
limit
data
decis
initi
continu
cytotox
chemotherapi
need
consid
individu
care
radiat
treatment
affect
immun
system
highdos
bodi
irradi
signific
risk
factor
progress
lower
respiratori
tract
infect
respiratori
syncyti
viru
rsv
hematopoiet
cell
transplant
lymphocyt
affect
extern
beam
radiat
result
radiationinduc
lymphopenia
becauselymphocyt
expos
irradi
field
direct
toxic
effect
phenomenon
report
occur
patient
undergo
convent
extern
beam
radiat
risk
mitig
use
proton
beam
therapi
stereotact
bodi
radiat
hypofraction
clear
guidelin
continu
initi
radiat
therapi
pandem
case
review
individu
level
riskbenefit
analysi
immunotherapi
treat
certain
cancer
type
includ
immun
checkpoint
inhibitor
tcell
transfer
therapi
vaccin
immunemodul
welldefin
guidelin
continu
initi
immunotherapi
pandem
howev
side
effect
therapi
may
serv
guid
decis
make
basi
side
effect
due
hyperactiv
tcell
respons
reactiv
direct
normal
immun
checkpoint
inhibitor
rare
side
effect
thrombocytopenia
pneumon
tcell
transfer
therapi
consist
tumorinfiltr
lymphocyt
til
chimer
antigen
receptor
car
tcelltherapi
side
effect
til
includ
prolong
lymphopenia
car
tcell
therapi
lead
cytokin
releas
cancer
vaccin
associ
minim
final
certain
immunemodul
agent
caus
thrombocytopenia
anemia
leukopenia
vascular
permeabl
lead
pleural
effus
pulmonari
interestingli
immunemodul
agent
diminish
inflamm
infect
shown
therapeut
promis
mice
model
infect
variou
influenza
sever
viral
respiratori
diseas
highest
morbid
mortal
observ
patient
hematopoiet
stem
cell
transplant
hsct
treatment
essenti
elimin
host
immun
system
replac
donor
patient
vulner
infect
first
month
transplant
recoveri
baselin
extend
year
specif
cancer
patient
particularli
high
risk
infect
due
cancer
type
treatment
patient
blood
malign
involv
immun
system
cell
lymphoma
aplast
anemia
myeloma
leukemia
vulner
infect
virtu
cancer
janu
kinas
inhibitor
jaki
bruton
tyrosin
kinas
inhibitor
btki
use
treatment
certain
cancer
includ
leukemia
lymphoma
also
caus
immunosuppress
inhibit
cytokin
growth
factor
signal
pathway
inhibit
bcell
matur
respect
nosocomi
infect
common
cancer
patient
increas
risk
viral
bacteri
fungal
patient
hospit
suscept
variou
respiratori
infect
human
rsv
influenza
b
virus
parainfluenza
viru
human
metapneumoviru
patient
undergon
hsct
acquir
parainfluenza
virus
lower
respiratori
tract
involv
greater
likelihood
respiratori
failur
addit
hsct
patient
communityacquir
pulmonari
viral
infect
sever
lower
respiratori
tract
involv
late
airway
outflow
obstruct
multipl
fungal
bacteri
postsurg
infect
common
often
sever
complic
cancer
patient
depend
type
locat
tumor
size
lymph
node
involv
organ
involv
subsequ
infecti
complic
rang
minor
moder
bevacizumab
angiogenesi
inhibitor
work
block
vascular
endotheli
growth
factor
vegf
caus
signific
delay
wound
heal
oblig
time
surgic
resect
variou
cancer
type
surgeri
tumor
locat
also
signific
effect
postop
infect
oral
maxillofaci
tumor
resect
complex
reconstruct
radic
neck
dissect
prolong
length
surgeri
hour
need
blood
transfus
associ
infect
rate
younger
cancer
survivor
often
robust
reconstitut
immun
system
compar
older
survivor
howev
survivor
age
higher
rate
infecti
complic
compar
noncanc
counterpart
cancer
survivor
like
hospit
respiratori
increas
particul
matter
pollut
least
time
like
develop
sepsi
increas
infectiousrel
mortal
cancer
patient
infect
may
increas
morbid
mortal
noncanc
patient
infect
liang
et
report
chines
nationwid
analysi
cancer
patient
infect
analysi
case
includ
patient
cancer
histori
patient
unknown
cancer
treatment
patient
recent
cancer
treatment
cancer
patient
older
histori
smoke
dyspnea
advanc
comput
tomographi
ct
scanfind
without
cancer
report
patient
higher
risk
sever
event
icu
admiss
mechan
ventil
death
patient
recent
cancer
treatment
experienc
sever
event
patient
cancer
exhibit
faster
clinic
deterior
vs
day
small
studi
sampl
size
age
bia
year
cancer
group
versu
year
noncanc
group
higher
rate
smoke
cancer
limit
extern
valid
generaliz
find
recent
studi
william
et
creat
model
estim
mortal
risk
agematch
cancer
patient
infect
articlewa
base
data
chines
cdc
italian
public
health
author
cohort
diamond
princess
cruis
ship
william
et
demonstr
strong
effect
age
mortal
year
increas
cfr
due
cancer
chemotherapi
conclud
cancer
patient
mortal
compar
cancerfre
patient
increas
mortal
greater
purport
aggreg
benefit
solid
tumor
chemotherapi
malign
sever
immun
deficit
like
greatest
risk
includ
lymphoma
leukemia
multipl
myeloma
sever
viral
respiratori
diseas
highest
morbid
mortal
found
patient
myelosuppress
hematopoiet
cell
risk
factor
lower
respiratori
tract
diseas
includ
age
year
graft
versu
host
diseas
corticosteroid
use
neutropenia
lymphopenia
effect
immun
respons
viral
infect
depend
activ
tcell
assist
clear
infect
approxim
million
case
tobaccoassoci
cancer
report
unit
state
lung
cancer
account
onethird
case
major
also
diagnos
chronic
obstruct
one
prospect
cohort
studi
determin
frequent
type
cancer
among
patient
lung
cancer
case
recent
data
demonstr
significantli
higher
angiotensinconvert
enzym
gene
express
former
smoker
lung
compar
nonsmok
bind
host
cell
receptor
critic
step
viral
cell
enzym
import
regul
immun
respons
particularli
acut
lung
murin
studi
observ
overexpress
lead
protect
effect
acut
lung
possibl
mechan
includ
prolifer
receptor
viru
bind
lead
greater
risk
perhap
increas
gene
express
confer
protect
immunolog
mechan
investig
need
determin
whether
smoker
greater
risk
acut
lung
injuri
viral
infect
care
must
taken
preoper
close
screen
patient
influenzalik
symptom
arriv
hospit
may
done
telephon
call
hospit
arriv
addit
screen
hospit
admiss
number
caregiv
direct
contact
patient
limit
necessari
throughout
periop
period
patient
suspect
confirm
requir
emerg
surgeri
avoid
preoper
hold
area
instead
transport
directli
design
oper
room
prefer
mobil
isol
unit
sign
post
entri
point
attempt
made
minim
health
care
staff
exposur
ensur
requir
staff
remain
ppe
essenti
health
care
provid
throughout
periop
period
ensur
airbornedropletcontact
isol
precaut
achiev
full
ppe
airway
manipul
includ
fittest
dispos
respir
power
airpurifi
respir
papr
goggl
face
shield
waterresist
gown
doubl
glove
protect
footwear
protocol
don
dof
ppe
must
strictli
adher
experienc
anesthesia
provid
perform
intub
especi
patient
sever
ill
video
laryngoscopi
consid
adequ
paralysi
ensur
intub
avoid
aerosol
gener
buck
patient
suspect
confirm
transfer
postanesthesia
care
unit
pacu
patient
recov
transfer
directli
airborn
isol
infect
room
minim
contamin
heat
moistur
exchang
filter
hmef
remov
airborn
particl
greater
appli
endotrach
tube
patient
left
much
time
possibl
allow
subsequ
patient
care
optim
decontamin
visitor
polici
may
fluid
restrict
rang
limit
number
visitor
per
patient
strict
novisitor
polici
determin
feder
state
mandat
except
may
consid
special
situat
endoflif
pediatr
care
date
treatment
patient
center
support
measur
sever
treatment
modal
current
avail
patient
exist
therapi
still
investig
certain
drug
proven
overal
treatment
determin
infect
sever
patient
comorbid
patient
mild
infect
selflimit
cours
recov
unev
home
manag
focu
patient
isol
prevent
spread
patient
moder
symptom
pneumonia
may
requir
hydroxychloroquin
azithromycin
addit
support
care
tabl
anecdot
hydroxychloroquin
azithromycin
shown
potenti
prophylaxi
treatment
patient
note
combin
drug
appear
reinforc
benefici
effect
significantli
decreas
viral
load
therebi
reduc
length
bronchodil
need
moder
infect
meter
dose
inhal
recommend
instead
nebul
treatment
limit
viral
spread
remdesivir
lopinavirritonavirar
current
recommend
patient
sever
symptom
includ
ard
requir
mechan
ventil
tabl
patient
sever
symptom
cytokin
releas
syndrom
ard
acut
lung
injuri
high
level
inflammatori
marker
start
refractori
sever
infect
worsen
symptom
interferon
convalesc
plasma
consid
tabl
previous
mention
cancer
patient
immunocompromis
state
like
present
sever
diseas
state
like
pneumonia
ard
may
warrant
intub
mechan
ventil
consider
aforement
drug
special
caution
must
taken
immunosuppress
cancer
patient
prescrib
tocilizumab
interferon
recommend
made
individu
us
cdc
recommend
avoid
steroid
treatment
american
heart
associ
aha
recommend
continu
angiotensinconvert
enzym
inhibitor
acei
angiotensin
receptor
blocker
arb
patient
alreadi
prescrib
periop
import
continu
prescrib
treatment
medic
understand
associ
consider
review
cancer
patient
base
latest
inform
knowledg
avail
medic
commun
time
pandem
continu
evolv
unfold
like
health
care
commun
face
addit
yet
unknown
challeng
imper
stay
abreast
develop
protect
frontlin
health
care
provid
provid
vulner
patient
care
need
best
chanc
surviv
return
optim
health
name
cindi
b
yeoh
md
contribut
author
help
studi
manuscript
includ
concept
work
draft
write
edit
revis
import
intellectu
content
well
final
approv
name
kathleen
j
lee
md
contribut
author
help
studi
manuscript
includ
write
edit
final
approv
name
elizabeth
f
rieth
md
contribut
author
help
studi
manuscript
includ
write
final
approv
name
rene
mape
contribut
author
help
studi
manuscript
includ
write
final
approv
name
anna
v
tchoudovskaia
dnap
contribut
author
help
studi
manuscript
includ
write
final
approv
name
gregori
w
fischer
md
contribut
author
help
studi
manuscript
includ
edit
final
approv
name
lui
e
tollinch
md
contribut
author
help
studi
manuscript
includ
edit
revis
import
intellectu
content
well
final
approv
manuscript
handl
thoma
r
vetter
md
mph
